CLINICAL TRIALS PROFILE FOR METHYLDOPA

All Clinical Trials for methyldopa

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117546 ↗	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia	Unknown status	Radboud University	Phase 4	2005-09-01	A history of preeclampsia is associated with a low plasma volume and higher sympathetic activity. Methyldopa will suppress sympathetic activity to normal values. In this study, the researchers will test that effect on the total cardiovascular balance.
NCT00157521 ↗	L-Arginine in Pre-Eclampsia	Completed	Mario Negri Institute for Pharmacological Research	Phase 3	2002-09-01	Pre-eclampsia is a disorder unique to pregnancy affecting both the mother and the fetus. Hypertension, proteinuria and edema are the most common and well-known maternal clinical symptoms. The incidence is approximately 6-8%. Pre-eclampsia is one of the leading causes of maternal and fetal mortality and morbidity associated with pregnancy throughout the world. The pathophysiology is unknown. At present, the most effective treatment is immediate delivery. The researchers' studies contributed to the demonstration that the vasodilator nitric oxide (NO) is important for correct placentation and that less nitric oxide (NO)- dependent vasodilation and an excess formation of reactive oxygen species explain poor placenta perfusion in pre-eclampsia. This reduced NO activity and increased oxidative stress in pre-eclamptic placenta is related to low bioavailability of L-arginine, the NO precursor. In this pilot study the researchers want to evaluate whether the administration of L-arginine to women with a clinical diagnosis of preeclampsia might restore physiological NO production in the placenta and ameliorate the pregnancy outcome.
NCT00194974 ↗	Treatment Targets for Chronic Hypertension in Pregnancy	Withdrawn	Weill Medical College of Cornell University	Phase 1/Phase 2	2004-07-01	This project is a clinical study of women with high blood pressure who become pregnant. Preeclampsia is a syndrome developing at the end of a pregnancy characterized by an abrupt rise in blood pressure (BP), blood clotting and kidney dysfunction, and may result in premature delivery, infant death, and maternal bleeding, kidney failure and stroke. The goal is to determine whether lowering blood pressure to a normal pressure of 120/80 is associated with a lower incidence of preeclampsia. Women who are completely healthy have a 5% chance of developing preeclampsia, however women with preexisting high blood pressure have a 25% chance of this complication. Several studies, including our own suggest that higher blood pressure early in pregnancy (
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	Afshan B. Hameed, M.D.	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	University of California, Irvine	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.

Clinical Trial Conditions for methyldopa

Condition Name

Condition Name for methyldopa
Intervention	Trials
Preeclampsia	4
Pre-eclampsia	3
Hypertension	2
Hypertension in Pregnancy	2

Condition MeSH

Condition MeSH for methyldopa
Intervention	Trials
Pre-Eclampsia	12
Hypertension, Pregnancy-Induced	6
Hypertension	6
Eclampsia	4

Clinical Trial Locations for methyldopa

Trials by Country

Trials by Country for methyldopa
Location	Trials
United States	5
Brazil	3
Netherlands	2
India	2
Nigeria	1

Trials by US State

Trials by US State for methyldopa
Location	Trials
New York	2
Colorado	1
Tennessee	1
California	1

Clinical Trial Progress for methyldopa

Clinical Trial Phase

Clinical Trial Phase for methyldopa
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	7
Phase 3	1

Clinical Trial Status

Clinical Trial Status for methyldopa
Clinical Trial Phase	Trials
Completed	9
Withdrawn	3
Unknown status	2

Clinical Trial Sponsors for methyldopa

Sponsor Name

Sponsor Name for methyldopa
Sponsor	Trials
Bill and Melinda Gates Foundation	2
University of British Columbia	2
Cairo University	1

Sponsor Type

Sponsor Type for methyldopa
Sponsor	Trials
Other	31
Industry	3
NIH	1

Methyldopa (Methyldopа): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is the current clinical-trial landscape for methyldopa?

No new late-stage or pivotal clinical-trial readouts for methyldopa were identified in the structured trial registries indexed in publicly accessible sources during the last update cycle. Methyldopa’s clinical use remains anchored in older development-era evidence rather than current, sponsor-driven phase development.

Practical implication for R&D and licensing: commercial upside from “new clinical data” is constrained by the absence of a visible, active modern development pipeline in the public trial record.

Trial activity snapshot (public registry visibility)

Registry (public)	What is visible	Typical interpretation
ClinicalTrials.gov	No clear signal of recent, active phase 3/registrational studies in the accessible record	Methyldopa is not in a visible, near-term lifecycle expansion via new efficacy/safety trials
EU Clinical Trials Register / other indexed sources	No clear, recent registrational program surfaced in accessible indexing	Same constraint as above

How does the evidence profile shape regulatory and commercial prospects?

Methyldopa is an established antihypertensive. Its regulatory posture is legacy-based, with use and labeling supported by older evidence and broad clinical adoption history rather than fresh confirmatory programs.

Key positioning

• Drug class: central alpha-2 adrenergic agonist (ATC: C02AB01) [1]
• Core indication: hypertension, including pregnancy-associated hypertension in standard clinical practice history (legacy label context) [1]
• Modern adoption pattern: generic penetration and low differentiation typically limit new entrant leverage absent a new formulation, delivery, or combination claim.

Where does methyldopa compete in market access terms?

Methyldopa competes in hypertension across a crowded generic landscape. The highest “switching power” comes when payers or formularies require pregnancy-safe options, or where specific guideline use supports older agents.

Therapeutic competition map (substitute classes)

Substitute cluster	Competitive pressure point
Generic ACE inhibitors, ARBs, thiazides, calcium channel blockers	Pricing pressure in general hypertension lines
Pregnancy-leaning antihypertensives (legacy practice)	Methyldopa retains relevance when preferred pregnancy options are needed

What does the market look like for methyldopa today?

Methyldopa’s market is driven by:

• Generic availability and price compression
• Continued use in pregnancy-related hypertension workflows in jurisdictions that still route to methyldopa
• Broad availability and entrenched clinician familiarity

Result: methyldopa behaves like a mature, low-to-mid value product category where growth is usually tied to country-level prescribing persistence and population coverage, not to innovation.

Market structure

Segment	Likely role for methyldopa
Hospital and obstetric pathways (pregnancy hypertension)	Higher relative share versus general outpatient hypertension
General hypertension (non-pregnancy)	Low relative share due to generic competition and newer standard-of-care patterns

Who is the buyer and what do they pay for?

• Primary buyers: national health systems, major wholesalers, and hospital formularies
• Payment dynamics: tend to favor lowest acquisition cost within formulary buckets (generic substitution)

Commercial leverage points

1. Formulary retention: remaining on pregnancy and resistant-hypertension lists
2. Supply continuity: stable manufacturing and consistent availability
3. Unit economics: low cost per dose, bulk purchasing terms

What is the projection for methyldopa over the next 3 to 7 years?

Because methyldopa is mature and generic, the most defensible projection model is “volume-stable to modestly declining with pricing drag,” with regional variation depending on guideline adherence and prescribing habits.

Projection framework

• Base case: modest volume erosion due to substitution to other low-cost generics and guideline evolution, partially offset by obstetric workflow stability.
• Price case: continued downward or flat pricing with periodic tender resets.
• Net outcome: low single-digit to mid single-digit annual net market growth in value is possible only in markets where volume holds and tender pricing stabilizes; otherwise value may drift down.

Directional projection

Time horizon	Value outlook	Volume outlook	Risk drivers
1 to 2 years	Flat to slight decline	Slight decline or stable	Tender pressure, prescribing shifts
3 to 5 years	Slight decline to flat	Slight decline	Continued substitution and generics competition
5 to 7 years	Flat to decline	Flat to slight decline	Market maturation; no visible innovation pipeline

What could change the trajectory?

Without new registrational evidence, the largest swing factors for methyldopa are operational and market-structure changes.

Change levers

• National guideline updates that either maintain or remove methyldopa as a pregnancy hypertension option
• Supply disruptions that briefly lift pricing and formularies’ reliance
• New formulation differentiation (if any) that can win tender advantage (not evidenced from a visible modern trial pipeline)

Where are the patents and exclusivity dynamics likely to sit?

Methyldopa has a long history as an older generic drug. Patent protection is not the main commercial driver at this stage; current market dynamics are dominated by:

• Ongoing generic manufacturing and tender pricing
• Brand vs generic naming distinctions that vary by jurisdiction

Clinical development vs. lifecycle strategy: what is the actionable conclusion?

For investors or R&D sponsors evaluating methyldopa specifically, the public clinical trial record offers limited near-term catalysts. The highest-return strategies in mature generics typically center on:

• Formulation improvements that reduce dosing burden (if supported by regulatory pathways)
• Supply and manufacturing reliability
• Targeted market access in pregnancy-related hypertension protocols

No public signal supports a near-term, sponsor-led registrational clinical pathway for methyldopa.

---

Key Takeaways

• Public trial registries do not show a visible modern phase 3 or registrational pipeline for methyldopa in the latest accessible update cycle.
• Methyldopa’s commercial outlook is tied to generic pricing, formulary retention, and persistence of pregnancy hypertension workflows rather than innovation-led demand.
• Near-term market value projection is flat to slightly down, with volume stable to modestly declining.
• The main upside lever is not clinical novelty but tender and guideline persistence, plus any manufacturing or formulation strategy that can win cost-and-availability position.

FAQs

1. Is methyldopa in active phase 3 clinical development?
   No clear, recent phase 3 registrational signal is visible in publicly indexed trial records.

2. What drives methyldopa demand today?
   Generic hypertension coverage and continued use patterns in pregnancy-related hypertension protocols.

3. How does pricing typically behave for mature generic antihypertensives like methyldopa?
   Tender cycles and substitution usually drive price compression, with value depending on volume resilience.

4. What is the highest-impact “watch item” for methyldopa over the next 5 years?
   Guideline and formulary decisions in pregnancy hypertension, plus tender pricing stability.

5. Is patent life a primary determinant of methyldopa’s market growth?
   No. Market behavior is dominated by generic competition rather than active exclusivity.

---

References

[1] World Health Organization. (n.d.). ATC/DDD index: Methyldopa (C02AB01). WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/